As next-generation sequencing technologies become more adept at predicting response to ICB-based therapy in sarcoma, it is important to consider the implications of “immune-hot” tumors for the development of potential toxicities, especially as combination immunotherapies are more likely to cause irAEs than anti-PD-1 treatment alone. The gene discussed is PDCD1; the disease is sarcoma.